featured
Efficacy and Safety of Ligelizumab for the Treatment of Adults and Adolescents With Chronic Spontaneous Urticaria
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The Lancet
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials
Lancet 2023 Nov 23;[EPub Ahead of Print], M Maurer, LF Ensina, AM Gimenez-Arnau, G Sussman, M Hide, S Saini, C Grattan, D Fomina, D Rigopoulos, F Berard, GW Canonica, H Rockmann, C Irani, JC Szepietowski, J Leflein, JA Bernstein, JG Peter, K Kulthanan, K Godse, L Ardusso, O Ukhanova, P Staubach, R Sinclair, S Gogate, SF Thomsen, T Tanus, YM Ye, A Burciu, A Barve, D Modi, E Scosyrev, E Hua, K Letzelter, V Varanasi, M Patekar, T SeverinFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.